EMA: New product-specific guidances [BE/BA News]

posted by Helmut Homepage – Vienna, Austria, 2022-04-08 17:17 (416 d 03:48 ago) – Posting: # 22918
Views: 3,418

Dear all,

on April 04 the EMA published revised draft product-specific guidances for ibuprofen, paracetamol, and tadalafil. In the footnote on page 1 we find:

* This revision concerns defining what is meant by ‘comparable’ Tmax as an additional main pharmacokinetic vari­able in the bioequivalence assessment section of the guideline.

Then:

Bioequivalence assessment: Comparable median (≤ 20% difference) and range for Tmax.


See this article why I consider this invention crap.
In short: tmax follows a discrete distribution on an ordinal scale. Calculating the ratio of values is a questionable procedure (strictly speaking not an allowed operation at all: Only addition, subtraction, ranking are).

[image]End of consultation 31 July 2022.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,616 posts in 4,740 threads, 1,610 registered users;
26 visitors (0 registered, 26 guests [including 8 identified bots]).
Forum time: 21:05 CEST (Europe/Vienna)

Do not worry about your difficulties in mathematics.
I can assure you mine are still greater.    Albert Einstein

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5